Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Nippon Kayaku Initiates PIII Study of NK105 for Breast Cancer
July 18, 2012
- Chairman Humer of Roche Criticizes Drug Pricing Policy in Japan as“Extremely Negative”
July 18, 2012
- Nippon Kayaku Launches New Specification of Generic Kytril
July 18, 2012
- China to Overtake Japan as Second-Biggest Drug Market by 2016: IMS Health
July 18, 2012
- MSD to Launch Oral Rotavirus Vaccine RotaTeq on July 20
July 18, 2012
- Janssen Applies for HIV Drug Prezista Naive Tablet 800 mg
July 17, 2012
- Otsuka HD’s Vice Chairman Otake Resigns for “Personal Reasons”
July 17, 2012
- Bioventure Industry Caught in Negative Spiral: DBJ Report
July 17, 2012
- Cumulative Sales of Japan’s 1st Emergency Contraceptive NorLevo Nears 50,000 Packs in 1 Year
July 16, 2012
- RIJ Plans World’s First Trial of iPS Cell Therapy in Men: President & CEO Kagimoto
July 16, 2012
- Shionogi Announces Positive Results of Second PIII Study for Dolutegravir
July 13, 2012
- Daiichi Sankyo to Receive METI’s Grant for Its Biopharmaceutical Production Facility Expansion
July 13, 2012
- Astellas to Develop Companion Diagnostic Agents in Collaboration with Other Companies: President Hatanaka
July 13, 2012
- Yoshindo to Develop Biopharmaceutical Business in 3 Steps: President Shimomura
July 13, 2012
- Taiho, Teikoku Form Alliance for Cancer Pain Reliever
July 12, 2012
- Teijin Pharma to Boost New Drug Ratio to More than 50%, Prepare “Post-Feburic” Products: President Arao
July 12, 2012
- Micro Marketing Method to Be Potentially Effective in Future: Ninomiya of Novartis Pharma
July 12, 2012
- Bayer HealthCare Initiates Multinational PIII Trial for Hemophilia A Treatment BAY94-9027
July 12, 2012
- Nippon Chemiphar Aiming to Boost Generic Drug Sales to 30 Billion Yen in FY2014: President Yamaguchi
July 12, 2012
- Shionogi Files Lawsuit against InterMune of US over Royalties Payment
July 12, 2012
ページ
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…